Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich et al. · Archives of Dermatological Research · 2010 · 886 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

James G. Krueger, Scott Fretzin, Mayte Suárez‐Fariñas et al. · Journal of Allergy and Clinical Immunology · 2012 · 380 citations · Full text

Life Sciences, Dermatology, Immunology +14

Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies

Jorge R. Georgakopoulos, Michelle Phung, Arvin Ighani et al. · Journal of the American Academy of Dermatology · 2018 · 54 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

When IL‐17 inhibitors fail: Real‐life evidence to switch from secukinumab to adalimumab or ustekinumab

Giovanni Damiani, Rosalynn R.Z. Conic, Valerio De Vita et al. · Dermatologic Therapy · 2018 · 43 citations · Full text

Medicine, Dermatology, Immunology +17

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · American Journal of Clinical Dermatology · 2017 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11